Cellbion
308430
Company Profile
Business description
Cellbion is a radiopharmaceutical innovation engaged in the development and commercialization of radioligand therapies to address unmet medical needs, focusing on improving patient outcomes and advancing healthcare through groundbreaking research and cutting-edge technology. Its pipeline products targeted indications are Prostate Cancer radiotherapy, Solid Tumors Diagnosis, Multiple Cancer types, and Others.
Contact
103, Daehak-ro
6th Floor
Jongno-gu
Seoul03080
KORT: +82 27433311
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,660.30 | 22.50 | 0.26% |
| CAC 40 | 7,759.41 | 20.31 | -0.26% |
| DAX 40 | 23,962.87 | 29.64 | 0.12% |
| Dow JONES (US) | 42,215.73 | 117.03 | 0.28% |
| FTSE 100 | 8,732.40 | 15.95 | 0.18% |
| HKSE | 23,191.86 | 381.52 | -1.62% |
| NASDAQ | 19,175.87 | 74.93 | 0.39% |
| Nikkei 225 | 37,965.10 | 467.88 | -1.22% |
| NZX 50 Index | 12,418.89 | 137.58 | 1.12% |
| S&P 500 | 5,912.17 | 23.62 | 0.40% |
| S&P/ASX 200 | 8,434.70 | 24.90 | 0.30% |
| SSE Composite Index | 3,347.49 | 15.96 | -0.47% |